Elsevier

The Lancet

Volume 343, Issue 8906, 7 May 1994, Pages 1122-1126
The Lancet

Articles
Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer

https://doi.org/10.1016/S0140-6736(94)90233-XGet rights and content

Abstract

In Japan the standard adjuvant treatment after resection of gastric cancer is intravenous mitomycin plus oral fluorouracil. We have assessed the efficacy of protein-bound polysaccharide (PSK) in addition to standard chemotherapy in patients who had undergone curative gastrectomy at 46 institutions in central Japan. 262 patients were randomly assigned standard treatment alone or with PSK. The minimum follow-up time was 5 years (range 5-7 years). PSK improved both the 5-year disease-free rate (70 7 vs 59 4% in standard treatment group, p=0 047) and 5-year survival (73·0 vs 60·0%, p=0·044). The two regimens had only slight toxic effects, consisting of nausea, leucopenia, and liver function impairment, and there were no significant differences between the groups. The treatments were clinically well tolerated and compliance was good. Addition of PSK to adjuvant chemotherapy with mitomycin and fluorouracil is beneficial as treatment after curative gastrectomy.

References (25)

  • International Union Against Cancer: TNM atlas

    (1985)
  • H. Endoh et al.

    Production of antiserum against antitumour protein-bound polysaccharide preparation, PSK (Krestin) and its pharmacological application

    Int J Immunopharmacol

    (1988)
  • Cited by (268)

    • An acetylated mannan isolated from Aloe vera induce colorectal cancer cells apoptosis via mitochondrial pathway

      2022, Carbohydrate Polymers
      Citation Excerpt :

      Moreover, due to their low toxicity and rarity of side effects, natural polysaccharides have been extensively studied as a class of potential anti-tumor agents (Yu, Shen, Song, & Xie, 2018). Several polysaccharide extracts from plants, animals, and fungi have been approved for the adjuvant treatment of cancers in clinical trials, including Poria cocos polysaccharide, Lentinan, Ginseng polysaccharide, and Polysaccharide Kreha (PSK) (Nakazato, Koike, Saji, Ogawa, & Sakamoto, 1994; Yu et al., 2018). Poria cocos polysaccharide oral solution, which has been provided as an over-the-counter health care product for decades in China, has been approved by the National Medical Products Administration as a drug for cancer treatment (Li et al., 2019).

    • Immunomodulatory Properties of Plants and Mushrooms

      2017, Trends in Pharmacological Sciences
    • Immunochemotherapy benefits in gastric cancer patients stratified by programmed death-1 ligand-1

      2017, Journal of Surgical Research
      Citation Excerpt :

      The results of this meta-analysis suggest that adjuvant immunochemotherapy with PSK improves the survival of patients after curative resection (HR: 0.88; 95% CI: 0.79-0.98; P = 0.018).15 Studies also showed that administration of PSK was able to reduce the risk of cancer-related death by up to 38% for stage II and III patients.10,16 Our subpopulation analysis, which took various stages of the disease and PD-L1 expression into account, might partly explain the mixed results of the previous surgical series.15,17

    View all citing articles on Scopus
    1

    Participating centres and other investigators are listed at the end of the article.

    View full text